TScan Therapeutics

Historical price data

TScan Therapeutics is a clinical-stage biotech company focused on developing transformative TCR-T therapies for oncology, with a secondary research arm in autoimmunity. Founded in 2018, its core asset is a proprietary, high-throughput platform that discovers novel tumor antigens and therapeutic TCRs. Key achievements include an active Phase 1 trial for its lead candidate TSC-101 in post-transplant AML/MDS and FDA clearance for two additional heme candidates. The strategy leverages this platform to build a broad pipeline while advancing next-generation in vivo engineering approaches.

A proprietary, high-throughput discovery platform that systematically identifies novel tumor antigens and their cognate T cell receptors (TCRs) for oncology, and autoantigens for autoimmune disease research. It also enables the development of in vivo T cell engineering approaches.

TScan competes in the crowded TCR-T space against players like Adaptimmune and Immunocore, differentiating through its proprietary discovery platform. It also faces indirect competition from CAR-T leaders in hematology and a new wave of companies developing in vivo cell engineering technologies. Success hinges on demonstrating clinical validation of its novel targets and advancing its next-generation delivery approach.